Edition:
United States

Sartorius Stedim Biotech SA (STDM.PA)

STDM.PA on Paris Stock Exchange

83.35EUR
23 May 2018
Change (% chg)

€0.20 (+0.24%)
Prev Close
€83.15
Open
€83.15
Day's High
€83.45
Day's Low
€81.15
Volume
39,433
Avg. Vol
57,893
52-wk High
€84.40
52-wk Low
€50.13

Chart for

About

Sartorius Stedim Biotech SA is a France-based international provider of laboratory and process technologies and equipment. The Company covers the segments of biotechnology and mechatronics. Sartorius provides services which help customers to implement complex and quality-critical processes in biopharmaceutical production and... (more)

Overall

Beta: 0.51
Market Cap(Mil.): €5,404.52
Shares Outstanding(Mil.): 92.18
Dividend: 0.42
Yield (%): 0.72

Financials

  STDM.PA Industry Sector
P/E (TTM): 34.49 32.19 32.75
EPS (TTM): 1.70 -- --
ROI: 18.12 13.89 14.38
ROE: 21.44 16.72 16.07

BRIEF-Sartorius Stedim Biotech Net Profit Up at 47.1 Million Euros

* IN Q1 INCREASED ITS SALES REVENUE IN CONSTANT CURRENCIES BY 9.8% (REPORTED 4.6%) TO 281.1 MILLION EUROS.

Apr 24 2018

BRIEF-Sartorius Stedim Biotech And Penn State University Entered Into Collaborative Partnership

* SARTORIUS STEDIM BIOTECH AND PENN STATE UNIVERSITY ENTERED INTO COLLABORATIVE PARTNERSHIP TO ADVANCE MULTIDISCIPLINARY TEACHING AND RESEARCH IN BIOTECHNOLOGY Source text : https://bit.ly/2qygOm0 Further company coverage: (Gdynia Newsroom)

Apr 16 2018

BRIEF-Sartorius Stedim Biotech Launches New Ambr 250 High Throughput Bioreactor System

* LAUNCHES NEW AMBR 250 HIGH THROUGHPUT BIOREACTOR SYSTEM FOR PERFUSION CULTURE Source text: http://bit.ly/2FKA8C8 Further company coverage: (Gdynia Newsroom:)

Mar 14 2018

BRIEF-Sartorius Stedim Biotech 2017 Underlying EBITDA Up By 2.2%

* SARTORIUS STEDIM BIOTECH TARGETS CONTINUED PROFITABLE GROWTH - SALES REVENUE PROJECTED AT AROUND 2.8 BILLION EUROS IN 2025

Feb 21 2018

BRIEF-Sartorius Stedim Biotech Proposes Dividend For Fiscal 2017 Of 0.46 Euro Per Share

* ‍UNDER THIS PROPOSAL, TOTAL PROFIT DISTRIBUTED WOULD RISE BY 9.5% FROM EUR 38.7 MILLION TO EUR 42.4 MILLION.​ Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

Feb 15 2018

BRIEF-Sartorius Stedim Biotech FY EBITDA Up At ‍​294.9 Million Euros

* FY EBITDA EUR ‍​294.9 MILLION VERSUS EUR 288.7 MILLION YEAR AGO

Jan 31 2018

BRIEF-Abzena Selects Sartorius Stedim Biotech To Equip Sites In San Diego And Bristol

* ABZENA SELECTS SARTORIUS STEDIM BIOTECH TO EQUIP US BASED DVLPT AND MANUFACTURING SITES IN SAN DIEGO AND BRISTOL

Jan 04 2018

Earnings vs. Estimates